References
- Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
- Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
- Woloshin S, Schwartz LM, Kerin K, Welch HG. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States. J. Gen. Intern. Med.22(2), 197–204 (2007).
- Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
- Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med.357(15), 1477–1486 (2007).
- Ward S, Lloyd Jones M, Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess.11(14), 1–160, iii–iv (2007).
- Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ333(7579), 1145 (2006).
- Chan KY, Boucher ES, Gandhi PJ, Silva MA. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am. J. Health Syst. Pharm.61(16), 1676–1681 (2004).
- van Hout BA, Simoons ML. Cost–effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur. Heart J.22(9), 751–761 (2001).
- Blake GJ, Ridker PM, Kuntz KM. Potential cost–effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med.114(6), 485–494 (2003).